References
- Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115:2523–30.
- Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41:269–85.
- Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol. 2003;139:66–70.
- Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol. 2002;146:20–3.
- Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149:1207–20.
- Vanharanta S, Massague J. Field cancerization: something new under the sun. Cell. 2012;149:1179–81.
- Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727–30.
- Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol. 2015;29:3–8.
- LEO Pharma. Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information 2015. Available from https://www.picato.com/_pdf/PrescribingInformation.pdf. Accessed August 10, 2015.
- Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–19.
- Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.
- Bertelsen M, Stahlhut M, Grue-Sorensen G, et al. Ingenol disoxate: a novel 4-isoxazolecarboxylate ester of ingenol with improved properties for treatment of actinic keratosis and other non-melanoma skin cancers. Dermatol Ther. 2016;6:599–626.
- Sinnya S, Tan JM, Prow TW, et al. A randomised, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Br J Dermatol. 2016;174:305–11.
- Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;4:207–19.
- Weiss J, Ulrich M, Bukhalo M, Osterdal ML, Petersen AH, Hanke CW. A dose finding trial with a novel ingenol derivative (LEO 43204) for field treatment of actinic keratosis on the scalp. J Am Acad Dermatol. 2016;74:AB192.
- Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13:154–60.
- Anderson L, Jarrett M, Schmieder G, et al. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100 cm2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19–29.
- Augustin M, Tu JH, Knudsen KM, et al. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015;72:816–21.
- Hanke WC, Norlin JM, Mark Knudsen K, et al. Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27:450–5.